Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722436 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL4290928 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6165925 | 0.77 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL66707 | 0.77 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL11120206 | 0.76 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL971269 | 0.75 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL7991192 | 0.75 | CXCR3 (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL3647069 | 0.75 | — | — | |
| SCHEMBL10378958 | 0.74 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL10569720 | 0.73 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250261684-A1 | SMOKELESS TOBACCO PRODUCT FOR ORAL USE AND SOFT CAPSULE USED THEREIN | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2025-08-21 | — | — | US | disclosed |
| US-20250120427-A1 | CARYOPHYLLENE-CONTAINING COMPOSITION | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
| WO-2025070466-A1 | SEAMLESS CAPSULE FOR ORAL CAVITY | 森下仁丹株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4420534-A1 | SMOKELESS TOBACCO PRODUCT FOR ORAL USE AND SOFT CAPSULE USED THEREIN | Sunsho Pharmaceutical Co., Ltd. (JP) | 2024-08-28 | — | — | EP | disclosed |
| EP-4403170-A1 | CARYOPHYLLENE-CONTAINING COMPOSITION | Sunsho Pharmaceutical Co., Ltd. (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-113316398-B | Seamless capsule, filter and smoking article comprising same | 三生医药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118159258-A | Composition containing caryophyllene | 三生医药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20240180219-A1 | SEAMLESS CAPSULE STABLY DISINTEGRABLE EVEN IN HIGH-TEMPERATURE AND HIGH-HUMIDITY ENVIRONMENT, AND METHOD FOR PRODUCING THE SAME | MORISHITA JINTAN CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-3888475-B1 | SEAMLESS CAPSULE, AND FILTER AND SMOKING DEVICE INCLUDING SAME | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-4316472-A1 | DISINTEGRABLE SEAMLESS CAPSULE THAT IS STABLE EVEN IN HIGH-TEMPERATURE AND HIGH-HUMIDITY ENVIRONMENT, AND METHOD FOR PRODUCING SAID SEAMLESS CAPSULE | Morishita Jintan Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-3398585-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10111822-B2 | External dermal composition for anti-ageing and method for producing the same | Hayashibara Co., Ltd. (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2939657-B1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | HAYASHIBARA CO (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-20150342854-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2939657-A1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | Hayashibara Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20150266847-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9085545-B2 | Macrocyclic triene lactones having unconjugated triene structure, its production method and its synthetic intermediate | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20130324744-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2012115285-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-08-30 | — | — | WO | disclosed |
| JP-2001302475-A | COMPOSITION FOR ORAL CAVITY | LION CORP | 2001-10-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324744-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAS2R13, TAS2R40, TAS2R14 | ALDH1A1 2177/4885SMN1; SMN2 2549/4885NPC1 3977/4885 |
| US-20150266847-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAS2R13, TAS2R40, TAS2R14 | ALDH1A1 2177/4885SMN1; SMN2 2549/4885NPC1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.